MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/01.mph.0000212991.64435.f0

Медицинская библиотека · Journal of pediatric hematology/oncology · 2006

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.

Pranzatelli Michael R, Tate Elizabeth D, Travelstead Anna L, Barbosa Jerry, Bergamini Robert A, Civitello Lucy, Franz David N, Greffe Brian S, Hanson Robin D, Hurwitz Craig A, Kalinyak Karen A, Kelfer Howard, Khakoo Yasmin, Mantovani John F, Nicholson Stacy H, Sanders Joann M, Wegner Stephen

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: To determine if rituximab, an anti-CD20 monoclonal antibody, reduces cerebrospinal fluid (CSF) B-cell expansion in opsoclonus-myoclonus syndrome (OMS) and results in clinical improvement.

METHODS

Sixteen children with OMS and increased % CD20 B-cells in CSF received 4 rituximab infusions (375 mg/m IV) as add-on therapy to corticotropin (ACTH), intravenous immunoglobulins, or both, and were reevaluated 6 months later. Outcome measures were clinical (motor function, behavior, sleep) and immunologic (CSF and blood immunophenotype and Ig levels). Controls were 16 age-matched and sex-matched children, who did not have OMS.

RESULTS

After rituximab, 81% of OMS had a lower motor severity score, and 44% improved one severity category. Mean total score decreased by 44% (P = 0.0005). Rituximab reduced rage score, nighttime awakenings, and the number of children with opsoclonus, action myoclonus, drooling, gait ataxia, and rage. Despite a 51% reduction in ACTH dose, 9 of 11 children on ACTH did not relapse. The percentage of CSF CD19 (and CD20) B-cells was lowered in all children (undetectable in 6), with a 90% reduction in the group mean (P = 0.00003). CSF B-cells were no longer expanded compared with controls. In blood, CD19 B-cells decreased (-90%, P = 0.0003), as did the CSF:blood CD19 B-cell ratio (P = 0.00003). Serum IgM fell by 69% (below reference range), with no statistically significant change in IgG or IgA.

CONCLUSIONS

Rituximab seems efficacious and safe as adjunctive therapy for OMS. Selective targeting of CSF B lymphocytes represents a novel and valuable paradigm shift in the therapy for centrally mediated paraneoplastic disorders.

Для цитирования: Pranzatelli Michael R, Tate Elizabeth D, Travelstead Anna L, Barbosa Jerry, Bergamini Robert A, Civitello Lucy, Franz David N, Greffe Brian S, Hanson Robin D, Hurwitz Craig A, Kalinyak Karen A, Kelfer Howard, Khakoo Yasmin, Mantovani John F, Nicholson Stacy H, Sanders Joann M, Wegner Stephen. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.. Journal of pediatric hematology/oncology. 2006. DOI: 10.1097/01.mph.0000212991.64435.f0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.